GE11-Ori-Se NPs

**GE11-Ori-Se NPs** are a preclinical EGFR-targeted nanomedicine comprising the diterpenoid anticancer compound **oridonin** loaded into selenium nanoparticles functionalized with the EGFR-binding GE11 peptide. The nanoparticles preferentially enter EGFR-overexpressing cancer cells, accumulate in lysosomes, and release oridonin more readily under acidic conditions. In esophageal cancer cell and mouse xenograft studies, the formulation induced reactive oxygen species generation and mitochondria-associated apoptosis, suppressed EGFR-associated PI3K/AKT and Ras/Raf/MEK/ERK signaling, reduced tumor angiogenesis, and inhibited tumor growth. It was developed as an intravenously administered candidate for EGFR-overexpressing esophageal cancer.

Other names

GE11-Ori-Se NPsGE-11-Ori-Se NPsGE 11-Ori-Se NPsGE11 peptide-conjugated oridonin-loaded selenium nanoparticlesGE-11 peptide-conjugated oridonin-loaded selenium nanoparticlesGE 11 peptide-conjugated oridonin-loaded selenium nanoparticlesGE11 peptide-modified oridonin-nano selenium compoundGE-11 peptide-modified oridonin-nano selenium compoundGE 11 peptide-modified oridonin-nano selenium compoundGE11 polypeptide-modified oridonin-nano selenium compoundGE-11 polypeptide-modified oridonin-nano selenium compoundGE 11 polypeptide-modified oridonin-nano selenium compound